New Breast Cancer Drug Cuts Disease Return Risk by 53%

Women facing early-stage breast cancer just got powerful new hope in their fight against one of the most aggressive forms of the disease.

The FDA approved ENHERTU for two new uses in HER2-positive early breast cancer, marking the first major advance in years for patients trying to prevent their cancer from returning. The drug can now be given before surgery to shrink tumors and after surgery for patients who still have cancer cells remaining.

The results speak for themselves. In patients who had cancer remaining after initial treatment, ENHERTU reduced the risk of the disease coming back or spreading by 53% compared to the previous standard treatment. Three years later, over 92% of patients taking ENHERTU were cancer-free, compared to just under 84% with the older drug.

Dr. Shanu Modi from Memorial Sloan Kettering Cancer Center explained the breakthrough simply. "Our goal is to reduce the risk of recurrence for patients as early as possible to achieve the best long-term outcomes," she said. ENHERTU now offers two critical opportunities to stop cancer before it spreads.

The timing matters deeply. Despite HER2-positive early breast cancer being considered highly curable, up to one in four patients still see their cancer return. For years, doctors have had limited options to change that statistic.

When used before surgery, ENHERTU helped 67% of patients achieve complete tumor elimination, compared to 56% with standard chemotherapy. That 11% difference translates to real women getting another chance at a cancer-free life.

Why This Inspires

This approval represents more than new treatment options. It's the culmination of a decade-long effort to give patients tools to stop cancer at its earliest, most beatable stage.

Victoria Smart from Susan G. Komen, a leading breast cancer organization, captured what this means for families. "Providing patients with early breast cancer more options to help prevent progression to metastatic disease can lead to improved outcomes," she said. Preventing cancer from spreading remains one of the biggest challenges patients face.

ENHERTU has now transformed treatment across six different breast cancer settings in just seven years. From early detection to advanced disease, patients have more weapons in their arsenal than ever before.

For the estimated 300,000 women diagnosed with breast cancer in the US each year, this approval opens doors that didn't exist before, turning what once seemed inevitable into something preventable.